With the important exception of the specific subset of patients who are anti-PLA2R positive, have an eGFR >60 ml/min, no secondary cause of MN, and no diabetes—who likely do not benefit from a renal biopsy for therapeutic strategy—in the other categories, the need for a renal biopsy, despite a clinically suggestive diagnosis, is supported by the significant additional information that can be obtained from the histological findings. Here, PLA2R1 is linked to diabetes mellitus.